THERATECHNOLOGIES chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.81
Dividend & YieldN/AC$ (N/A)
Beta 1.48
Market capitalization 249.27M
Operating cash flow -11.93M
ESG Scores unknown

Company description

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

Sector: Healthcare - Industry: Drug Manufacturers—Specialty & Generic

Financial Ratios
Quick Ratio1.39
Working Capital-0.68
Return On Equity-1.79
Debt To Equity3.05
Fixed Asset Ratio0.32
Fixed Interest Cover-4.46

Financial data

Financial Statements

Cashflow Statement 2018-11-30 2019-11-30 2020-11-30 2021-11-30
Change To Liabilities 6.13M 6.18M 3.42M 5.55M
Total Cashflows From Investing Activities -9.92M -130k 4.78M -12.45M
Net Borrowings 49.65M -3.5M -4.07M -5.63M
Total Cash From Financing Activities 47.46M -6.81M -7.23M 34.56M
Change To Operating Activities -380k -812k -2.58M -3.02M
Issuance Of Stock 633k 110k 145k 47.34M
Net Income -4.7M -12.5M -22.67M -31.73M
Change In Cash 37.63M -10.34M -15.92M 7.66M
Effect Of Exchange Rate -8k -8k 83k 36k
Total Cash From Operating Activities 92k -3.39M -13.55M -14.48M
Depreciation 4.23M 7.5M 8.52M 8.75M
Change To Account Receivables -3.4M 831k -2.25M 1.85M
Other Cashflows From Financing Activities -2.83M -3.42M -3.31M -7.15M
Change To Netincome 2.2M 5.27M 6.87M 8.26M
Capital Expenditures -25k -1.22M -32k -127k

Income Statement 2018-11-30 2019-11-30 2020-11-30 2021-11-30
Research Development 10.84M 10.84M 18.02M 28.27M
Income Before Tax -5.97M -12.5M -22.65M -31.66M
Net Income -4.7M -12.5M -22.67M -31.73M
Selling General Administrative 27.52M 34.81M 39.09M 43.52M
Gross Profit 26.4M 42.02M 44.03M 51.45M
Ebit -3.56M -8.51M -17.96M -25.24M
Operating Income -3.56M -8.51M -17.96M -25.24M
Interest Expense -2.53M -4.99M -5.36M -5.66M
Income Tax Expense -1.27M 16k 63k
Total Revenue 45.22M 63.22M 66.05M 69.82M
Cost Of Revenue 18.82M 21.19M 22.02M 18.38M
Total Other Income ExpenseNet -2.41M -3.98M -4.69M -6.43M
Net Income From Continuing Ops -4.7M -12.5M -22.67M -31.73M
Net Income Applicable To Common Shares -4.7M -12.5M -22.67M -31.73M

Balance Sheet Statement 2018-11-30 2019-11-30 2020-11-30 2021-11-30
Total Liabilities 76.1M 92.72M 96.92M 101.45M
Total Stockholder Equity 35.01M 24.83M 3.22M 17.76M
Other Current Liabilities 1.04M 5.97M 6.68M 4.24M
Total Assets 111.12M 117.56M 100.14M 119.21M
Common Stock 286.83M 287.04M 287.31M 335.75M
Other Current Assets 1.29M 637k 520k 740k
Retained Earnings -264.97M -277.46M -300.13M -335.25M
Treasury Stock 4.36M 4.48M 3.98M 4.41M
Cash 39M 28.66M 12.74M 20.4M
Total Current Liabilities 26.87M 37.14M 41.92M 45.08M
Other Stockholder Equity 4.36M 4.48M 3.98M 4.41M
Property, Plant, and Equipment 101k 1.07M 3.48M 2.85M
Total Current Assets 73.61M 76.18M 64.81M 91.91M
Net Tangible Assets 2.8M -14.85M -28.63M -6.07M
Net Receivables 10.95M 10.12M 13.19M 10.93M
Accounts Payable 15.58M 13.11M 17.51M 15.53M


Insider Transactions

Here are the insider transactions of stock shares related to THERATECHNOLOGIES:

Filer Name Transaction Text Ownership Date Filer Relation Shares
Arena (Joseph)Acquisition or disposition in the public market at price 1.97 per share.D2022-10-21Director of Issuer2.5k
Svoronos (Dawn A)D2022-10-20Director of Issuer50k
Lafond (Jocelyn)Acquisition or disposition in the public market at price 2.21 per share.D2022-07-21Senior Officer of Issuer800
Lafond (Jocelyn)Acquisition or disposition in the public market at price 2.20 per share.D2022-07-21Senior Officer of Issuer6.2k
Lafond (Jocelyn)Acquisition or disposition in the public market at price 2.21 per share.D2022-07-21Senior Officer of Issuer3k
Lafond (Jocelyn)Exercise of options at price 0.29 per share.D2022-07-19Senior Officer of Issuer20k
Lafond (Jocelyn)Acquisition or disposition in the public market at price 2.14 per share.D2022-07-19Senior Officer of Issuer3k
Lafond (Jocelyn)D2022-07-19Senior Officer of Issuer7k
Holler (Frank A)Acquisition or disposition in the public market at price 2.54 per share.D2022-05-03Director of Issuer39k
Arena (Joseph)Acquisition or disposition in the public market at price 2.27 per share.D2022-05-02Director of Issuer4.9k
Arena (Joseph)Acquisition or disposition in the public market at price 2.31 per share.D2022-05-02Director of Issuer100

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to THERATECHNOLOGIES. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on THERATECHNOLOGIES

Here is the result of two systematic investment strategies applied to THERATECHNOLOGIES. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on THERATECHNOLOGIES

The following chart shows the equity curve of the two systematic investment strategies applied to THERATECHNOLOGIES:

THERATECHNOLOGIES automated entries

The systematic investment strategy that buys the first day of the month would give a performance of -17.85% on the backtest period.

Performance at glance

Performance

-17.85 %

Latent gain

-266.76 C$

Invested capital

1494.43 C$

Annualized return

-4.31 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on THERATECHNOLOGIES

This is the result of two momentum investment strategies applied to THERATECHNOLOGIES. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on THERATECHNOLOGIES

The following chart shows all the entries opened by the momentum investment system on THERATECHNOLOGIES:

THERATECHNOLOGIES momentum entries
  • The first momentum investment strategy would give -35.12% of return on THERATECHNOLOGIES. That represents -2105.92C$ of latent gain with 5996.96C$ of employed capital.
  • The second momentum investment strategy would give -22.96% of return on THERATECHNOLOGIES. That represents -976.42C$ of latent gain with 4252.16C$ of employed capital.
Performance at glance (1Q Momentum)

Performance

-35.12 %

Latent gain

-2105.92 C$

Invested capital

5996.96 C$

Annualized return

1.14 %
Performance at glance (2Q Momentum)

Performance

-22.96 %

Latent gain

-976.42 C$

Invested capital

4252.16 C$

Annualized return

-6.27 %

Momentum equity curve on THERATECHNOLOGIES

The following chart shows the equity curve of the two momentum strategies applied to THERATECHNOLOGIES:

THERATECHNOLOGIES momentum equity

Note: the dividends potentially given by THERATECHNOLOGIES are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on THERATECHNOLOGIES

The following chart shows the employed capital evolution of the two momentum strategies on THERATECHNOLOGIES since the beginning:

THERATECHNOLOGIES

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250C$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000C$.


Buy the dip strategy result on THERATECHNOLOGIES

Buy the dip entry openings on THERATECHNOLOGIES

THERATECHNOLOGIES

The performance achieved by the robo-advisor on THERATECHNOLOGIES is 2.45%. That represents 6.09$ of latent gain with 248.82C$ of employed capital. The following chart shows THERATECHNOLOGIES stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of THERATECHNOLOGIES, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

2.45 %

Latent gain

6.09 C$

Invested capital

248.82 C$

Annualized return

1.14 %

Equity curve of the strategy applied to THERATECHNOLOGIES

The following chart shows the result of the investment strategy applied to THERATECHNOLOGIES:

THERATECHNOLOGIES

Note: the dividends potentially given by THERATECHNOLOGIES are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on THERATECHNOLOGIES

The following chart shows the employed capital evolution since the beginning of the investment strategy on THERATECHNOLOGIES:

THERATECHNOLOGIES

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on THERATECHNOLOGIES

In this section, I will compare the three previous investment strategies applied to THERATECHNOLOGIES.

Equity curve comparison on THERATECHNOLOGIES

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

THERATECHNOLOGIES investment strategy comparison

Employed capital comparison on THERATECHNOLOGIES

THERATECHNOLOGIES investment comparison

Performance comparison on THERATECHNOLOGIES

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment -17.85% -266.76C$ 1494.43C$ -4.31%
Momentum 1 quarter -35.12% -2105.92C$ 5996.96C$ -9.01%
Momentum 2 quarters -22.96% -976.42C$ 4252.16C$ -6.27%
Non-directional 2.45% 6.09C$ 248.82C$ 1.14%
Annualized return comparison

Automatic investment

-4.31 %

Momentum 1Q

-6.27 %

Momentum 2Q

-6.27 %

Non-directional

1.14 %

Correlated stocks

Here are the most positively and negatively correlated stocks with THERATECHNOLOGIES:

Positive correlations

Most correlated stocks this year

  • THERATECHNOLOGIES

  • Most correlated stocks last 3 months

  • Schmitt Industries Inc
  • THERATECHNOLOGIES

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months


    Note: The algorithm computes the probability of correlation between THERATECHNOLOGIES and the other stocks. There may be false positives or some missing correlated stocks. If the price of THERATECHNOLOGIES does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name THERATECHNOLOGIES
    Country Canada
    City Montreal
    Address 2015 Peel Street
    Phone
    Website www.theratech.com
    FullTime employees 87
    Industry Drug Manufacturers—Specialty & Generic
    Sector Healthcare
    Exchange XTSE
    Ticker TH.XTSE
    Market

    THERATECHNOLOGIES ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown